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BACKGROUND: Effects of sodium- glucose cotransporter 2 inhibitors on reducing hospitalization for heart failure have been re-
ported in randomized controlled trials, but their effects on patients with heart failure with preserved ejection fraction (HFpEF) 
are unknown. This study aimed to evaluate the drug efficacy of luseogliflozin, a sodium- glucose cotransporter 2 inhibitor, in 
patients with type 2 diabetes mellitus and HFpEF.
METHODS AND RESULTS: We performed a multicenter, open- label, randomized, controlled trial for comparing luseogliflozin 
2.5 mg once daily with voglibose 0.2 mg 3 times daily in patients with type 2 diabetes mellitus suffering from HFpEF (left ven-
tricular ejection fraction >45% and BNP [B- type natriuretic peptide] concentrations ≥35 pg/mL) in a 1:1 randomization fashion. 
The primary outcome was the difference from baseline in BNP levels after 12 weeks of treatment between the 2 drugs. A total 
of 173 patients with diabetes mellitus and HFpEF were included. Of these, 83 patients were assigned to receive luseogliflozin 
and 82 to receive voglibose. There was no significant difference in the reduction in BNP concentrations after 12 weeks from 
baseline between the 2 groups. The ratio of the mean BNP value at week 12 to the baseline value was 0.79 in the luseogliflo-
zin group and 0.87 in the voglibose group (percent change, −9.0% versus −1.9%; ratio of change with luseogliflozin versus 
voglibose, 0.93; 95% CI, 0.78–1.10; P=0.26).
CONCLUSION: In patients with type 2 diabetes mellitus and HFpEF, there is no significant difference in the degree of reduction 
in BNP concentrations after 12 weeks between luseogliflozin and voglibose.
REGISTRATION: URL: https://www.umin.ac.jp/ctr/index.htm; Unique identifier: UMIN000018395.
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For the past 2 decades, a better prognosis was able to be achieved than was previously possible in patients with heart failure with reduced ejec-
tion fraction (EF) because of the advent of guideline- 
based medicine and device therapy. However, the 
effectiveness of these therapeutic agents has not 
been clarified in heart failure with preserved ejection 
fraction (HFpEF) in clinical trials.1–4 Furthermore, re-
cent guidelines suggest no effective medication for 
HFpEF.5,6
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Sodium- glucose cotransporter 2 (SGLT2) inhibitors, 
which are antidiabetic drugs for promoting urinary 
glucose excretion, have been suggested to reduce 
hospitalization for heart failure in patients with type 
2 diabetes mellitus in recent randomized controlled 
trials.7–9 Recently, a randomized study showed that 
dapagliflozin decreased worsening heart failure in pa-
tients with heart failure and a reduced EF, regardless of 
the presence or absence of diabetes mellitus.10 SGLT2 
inhibitors are being studied in large trials for HFpEF, but 
no detailed data on the effects of SGLT2 inhibitors in 
HFpEF have been obtained.
To investigate whether an SGLT2 inhibitor has 
preventative effects on heart failure beyond glucose- 
lowering effects in patients with HFpEF, we prospec-
tively compared luseogliflozin and alpha- glucosidase 
in the MUSCAT- HF (Management of Diabetic Patients 
with Chronic Heart Failure and Preserved Left 
Ventricular Ejection Fraction) trial. We compared the 
drug efficacy of luseogliflozin (an SGLT2 inhibitor) 
with voglibose (an alpha- glucosidase inhibitor), which 
have established safety for cardiovascular events11 
as control agents. BNP (B- type natriuretic peptide) 
was used as the index of the therapeutic effect in pa-
tients with type 2 diabetes mellitus and HFpEF. This 
study aimed to determine the therapeutic effect of 
this SGLT2 inhibitor on HFpEF in patients with type 2 
diabetes mellitus.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Study Design
Details of the study design have been published previ-
ously12 (Data S1 through S3).The MUSCAT- HF trial was 
a multicenter, prospective, open- label, randomized 
controlled trial for assessing the effect of luseogliflozin 
(2.5 mg once daily) compared with voglibose (0.2 mg 3 
times daily) on left ventricular load in patients with type 
2 diabetes mellitus and HFpEF. The change in ratio of 
BNP concentrations after administration of the study 
drug from baseline was used as a surrogate biomarker 
for heart failure (Figure S1 and Table S1). This study 
was approved by the Okayama University Graduate 
School of Medicine, Density and Pharmaceutical 
Sciences and the Okayama University Hospital Ethics 
Committee, as well as the ethics committee of each 
participating center. The investigation conforms with 
the principles outlined in the Declaration of Helsinki. 
This trial was registered in the University Hospital 
Medical Information Network Clinical Trial Registry 
(UMIN000018395).
Members of the steering committee also de-
signed the study and are responsible for its conduc-
tion. Significant adverse events that occurred within 
30  days after final administration of the study drug 
CLINICAL PERSPECTIVE
What Is New?
• The MUSCAT-HF (Management of Diabetic 
Patients with Chronic Heart Failure and 
Preserved Left Ventricular Ejection Fraction) 
study is the first prospective, multicenter, open-
label, randomized controlled trial to investigate 
the drug effect of an sodium-glucose cotrans-
porter 2 inhibitor, luseogliflozin, on BNP (B-type 
natriuretic peptide) concentrations as the pri-
mary outcome compared with an alpha-glu-
cosidase inhibitor, voglibose.
• We found that BNP concentrations decreased 
after initiation of either luseogliflozin or voglib-
ose; however, there was no significant dif-
ference in the degree of reduction in BNP 
concentrations after 12  weeks for luseogliflo-
zin and voglibose (percent change, −9.0% 
versus −1.9%; ratio of change with luseogliflo-
zin versus voglibose, 0.93; 95% CI, 0.78–1.10; 
P=0.26).
What Are the Clinical Implications?
• Our findings support no clear evidence of the 
effect of sodium-glucose cotransporter 2 in-
hibitors in reducing BNP concentrations at 
12 weeks in patients with type 2 diabetes mel-
litus with heart failure with preserved ejection 
fraction and a requirement of further investiga-
tions including ongoing larger randomized con-
trolled trials.
Nonstandard Abbreviations and Acronyms
BNP B-type natriuretic peptide
EF ejection fraction
eGFR estimated glomerular filtration rate
ESC European Society of Cardiology
E/e′  ratio of early mitral inflow velocity to 
mitral annular early diastolic velocity
HFpEF  heart failure with preserved 
ejection fraction
MUSCAT-HF  Management of Diabetic Patients 
with Chronic Heart Failure and 
Preserved Left Ventricular Ejection 
Fraction
SGLT2 sodium-glucose cotransporter 2
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or after 30 days with a suspicion of association with 
the study drug, as well as all pregnancies, were im-
mediately reported to the steering committee and the 
sponsor by the investigators, in accordance with the 
guidelines for good clinical practice.
Participants
Patients aged ≥20 years with requirement of additional 
treatment for type 2 diabetes mellitus, despite ongoing 
treatment, and HFpEF were eligible for participation. 
HFpEF was defined as a left ventricular EF ≥45%, BNP 
concentrations ≥35 pg/mL, and any symptoms, such 
as shortness of breath, orthopnea, and leg edema. 
The criterion of BNP concentrations was based on the 
fact that the definition of chronic heart failure accord-
ing to the European Society of Cardiology guidelines 
includes BNP concentrations ≥35  pg/mL.13 Patients 
with BNP concentrations <35 pg/mL; treatment with 
alpha- glucosidase inhibitors, SGLT2 inhibitors, gli-
nides, or high- dose sulfonylurea; renal insufficiency 
(estimated glomerular filtration rate [eGFR] <30  mL/
min per 1.73 m2); a history of severe ketoacidosis or 
diabetic coma within 6  months before participation; 
poorly controlled type 2 diabetes mellitus (hemoglobin 
A1c >9.0%); and hypertension were excluded (see full 
exclusion criteria in Data S1). All participants provided 
written informed consent before participation. Study 
candidates were assessed for eligibility within 4 weeks 
before enrollment.
Interventions and Study Procedures
Patients fulfilling all criteria who provided written in-
formed consent to participate in this study were en-
rolled and subsequently randomized (1:1) to receive 
luseogliflozin (2.5 mg once daily) or voglibose (0.2 mg 
3 times daily) in addition to their background medica-
tion. Luseogliflozin is an SGLT2 inhibitor, which has 
1600- fold selectivity of SGLT2 to SGLT1,14 and is cur-
rently approved or marketed in Japan, but not in North 
America and European countries. Randomization 
was performed using a computer- generated ran-
dom sequence web response system. Patients were 
stratified by age (<65  years, ≥65  years), baseline 
hemoglobin A1c values (<8.0%, ≥8.0%), baseline BNP 
concentrations (<100  pg/mL, ≥100  pg/mL), base-
line renal function (eGFR ≥60  mL/min per 1.73  m2, 
<60 mL/min per 1.73 m2), use of thiazolidine (yes or 
no), and presence or absence of atrial fibrillation and 
flutter at screening.
Laboratory data, ECGs, echocardiography, and 
patients’ vital signs, body weight, and waist circum-
ference were evaluated at 4 and 12 weeks after initi-
ation of study treatment. Safety and tolerability were 
assessed during the treatment period. After 12 weeks, 
expansion of follow- up for an additional 12 weeks was 
continued in patients who agreed. If a patient’s glyce-
mic control worsened after 4 weeks, the investigator 
increased the dose of allocated treatment (luseogli-
flozin 5  mg once daily or voglibose 0.3  mg 3 times 
daily) and other specific antidiabetic drugs, except for 
sulfonylureas. Investigators were also encouraged to 
treat all other cardiovascular risk factors according to 
the local standard of care. Under the following circum-
stances, the investigators evaluated the data and pa-
tient’s vital signs: (1) discontinuation of study treatment; 
(2) dose increase of specific treatment for heart failure; 
(3) initiation of new treatment for heart failure; and (4) 
withdrawal from the study. The permitted medications 
for treatment of heart failure included angiotensin- 
converting enzyme inhibitors, angiotensin receptor 
blockers, beta- blockers, diuretics, and mineralocorti-
coid/aldosterone receptor antagonists.
Outcomes
The primary outcome of this study was the change in 
ratio of BNP concentrations after 12  weeks of treat-
ment from baseline. The main safety outcomes were 
adverse events, including major adverse cardiovascu-
lar events, hypoglycemic adverse events (requiring any 
intervention), and urinary tract infection. Major adverse 
cardiovascular events included cardiovascular death, 
acute coronary syndrome, hospitalization for heart fail-
ure, and stroke. Details of the main safety outcomes 
are shown in Data S3. The main secondary outcomes 
of this study were the differences in the following pa-
rameters between 12 weeks and baseline: the ratio of 
early mitral inflow velocity to mitral annular early dias-
tolic velocity (E/e′), left ventricular EF, body weight, and 
hemoglobin A1c values. Further exploratory analysis 
is listed in Data S1. We also conducted analyses of 
exploratory clinical outcomes, including changes in 
systolic blood pressure, heart rate, eGFR, NT- proBNP 
(N- terminal pro- BNP) concentrations, high- sensitivity 
C- reactive protein concentrations, the ratio of early to 
atrial mitral inflow velocity, mitral annular early diastolic 
velocity, left atrial diameter, left atrial volume index, and 
left ventricular mass index.
Statistical Analysis
We estimated that the change in ratio of BNP concen-
trations in the luseogliflozin group would be 30% lower 
compared with that in the voglibose group according 
to previous studies of the effect of renin–angiotensin–
aldosterone system inhibitors on heart failure.15–17 The 
standard deviation of the natural logarithmic transfor-
mation of BNP was estimated as 0.83 on the basis of 
a previous study.17 A minimum of 172 patients (86 pa-
tients per group) were required to provide 80% power 
with a 2- sided α level of 0.05 by the Student t test 
between 2 groups. With 10% of patients estimated to 
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withdraw from participation during the study period, 
the final enrollment target was set at 190 patients (95 
patients per group).
Efficacy analysis was performed according to 
the treatment to which patients were randomly 
assigned based on the intention- to- treat analy-
sis. The primary outcome analysis was based on 
analysis of covariance for the change in ratio of 
BNP concentrations after 12 weeks from baseline. 
Adjusted covariates included the assigned treat-
ment (luseogliflozin, voglibose), baseline age (<65 or 
≥65 years), baseline hemoglobin A1c values (<8.0% 
or ≥8.0%), baseline BNP concentrations (<100 or 
≥100  pg/mL), baseline renal function (eGFR ≥60 
or <60 mL/min per 1.73 m2), use of thiazolidine at 
baseline, and presence or absence of atrial fibril-
lation and atrial flutter at baseline as stratified fac-
tors of randomization. A similar method was used 
to analyze the secondary outcomes. Furthermore, 
the same analysis as that for the primary outcome 
was performed for the change in ratio of BNP con-
centrations after 4 and 24 weeks from baseline as 
sensibility analyses. For safety analysis, the primary 
population was all patients who received at least 
1 dose of study drug. Analysis of safety outcomes 
(major adverse cardiovascular events, hypogly-
cemia, and urinary tract infection) was performed 
using the Cochran–Mantel–Haenszel test with the 
same stratification factors as those for the primary 
outcome. The consistency of drug effects was ex-
amined across 6 prespecified subgroups as strat-
ified factors of randomization and the presence 
or absence of prior atherosclerotic cardiovascular 
events. All comparisons and analyses were 2- sided 
with P<0.05 considered statistically significant. All 
statistical analyses were performed using IBM SPSS 
Statistics 24 (IBM, Armonk, NY) and Stata/SE 15.1 
for Mac (StataCorp, College Station, TX).
RESULTS
Study Population
Between December 2015 and September 2018, a total 
of 173 patients from 16 hospitals and clinics had been 
screened for this study. A total of 169 patients were en-
rolled in this study. Of these patients, 86 were assigned 
to receive luseogliflozin and 83 to receive voglibose. 
Three (1.8%) patients did not receive any doses of a 
study drug and were prospectively excluded from all 
analyses. The safety analyses included a total of 166 
patients. A total of 165 patients, with 83 in the luse-
ogliflozin group and 82 in the voglibose group, who 
had BNP measurements assessed at least once were 
included in the efficacy analyses (Figure 1). High study 
drug adherence was observed in each hospital visit 
among the study population; the mean administra-
tion rate was 96.8% (luseogliflozin: 98.3%, voglibose: 
95.2%).
The baseline characteristics of the patients are 
shown in Table 1. The baseline variables were sim-
ilar between the luseogliflozin and voglibose groups, 
except for the patients’ age because the majority of 
patients included in the study were aged ≥65 years. 
The mean age was significantly younger in patients 
in the luseogliflozin group than in the voglibose group 
(P=0.017). The rate of male sex was 66% and 59%, 
and the rate of patients with prior atherosclerotic 
cardiovascular disease was 59% and 62% in the lu-
seogliflozin and voglibose groups, respectively. The 
majority of patients had mild heart failure symptoms 
at baseline. A total of 160 (97%) patients were classi-
fied as New York Heart Association class II, with no 
significant difference between the 2 groups. There 
was no significant difference in baseline medications 
between the 2 groups. More than half of the patients 
of this study were treated with specific heart failure 
treatment drugs, such as angiotensin- converting 
enzyme inhibitors, angiotensin receptor blockers, 
and beta- blockers. Mineralocorticoid receptor an-
tagonists were used in almost 20% of the patients. 
Antidiabetic medication was administered in 103 
(62%) patients.
The mean systolic blood pressure and heart rate 
were not significantly different between the 2 groups. 
At baseline, the median BNP concentration was 63.7 
(interquartile range, 46.8–115.8) versus 75.1  pg/mL 
(interquartile range, 42.4–120) and the median NT- 
proBNP concentration was 203 (interquartile range, 
123–389) versus 200 pg/mL (interquartile range, 121–
502) between the luseogliflozin and voglibose groups, 
respectively. No significant differences were observed 
in any cardiac- related or other biomarker concentra-
tions and echocardiographic parameters between the 
2 groups.
Among all patients, the proportions of a left ven-
tricular mass index ≥115 g/m2 for men or ≥95 g/m2 for 
women, left atrial volume index >34 mL/m2, e′ <8 cm/s, 
and E/e′ ≥13 were 21%, 53%, 94%, and 39%, respec-
tively. The baseline echocardiographic parameters 
were similar between the luseogliflozin and voglibose 
groups.
Primary Outcome
BNP concentrations decreased over time in the lu-
seogliflozin group. A consistent decrease in BNP 
concentrations in the luseogliflozin group was ob-
served after 4 and 24 weeks from baseline (Table 2). 
However, there was no significant difference in the 
reduction in BNP concentrations after 4 or 12 weeks 
compared with baseline between the 2 groups. The 
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ratio of the mean BNP value at week 12 to the base-
line value was 0.79 in the luseogliflozin group and 
0.87 in the voglibose group (percent change, −9.0% 
versus −1.9%; ratio of change with luseogliflozin 
versus voglibose, 0.93; 95% CI, 0.78–1.10; P=0.26) 
(Figure 2).
Secondary and Safety Outcomes
The change in E/e′, left ventricular EF, body weight, 
and hemoglobin A1C levels after 12  weeks in the lu-
seogliflozin group were not significantly different from 
those in the voglibose group (Table 2). The main safety 
outcomes, including major adverse cardiovascular 
events, hypoglycemic adverse events, and urinary 
tract infection, were not significantly different between 
the groups (Table 2). No significant difference was ob-
served in other adverse events between the groups. 
However, the rate of gastrointestinal symptoms in the 
voglibose group was significantly higher than that in the 
luseogliflozin group (P=0.013). Exploratory hemody-
namic and biomarker outcomes are shown in Table 2. 
No significant differences were observed in the change 
in heart rate, eGFR, NT- proBNP concentrations, 
high- sensitivity C- reactive protein concentrations, E/A, 
e′, left atrial diameter, left atrial volume index, and left 
ventricular mass index between the groups. However, 
a significantly greater reduction in systolic blood pres-
sure after 12 weeks compared with baseline was ob-
served in the luseogliflozin group than in the voglibose 
group (P=0.036).
Subgroup Analyses
No statistical significance was observed in the interac-
tion between the effect of study drugs and prespeci-
fied patient subgroups (Figure 3).
DISCUSSION
The MUSCAT- HF study is the first prospective, multi-
center, open- label, randomized, controlled trial to inves-
tigate the drug effect of an SGLT2 inhibitor, luseogliflozin, 
on BNP concentrations as the primary outcome com-
pared with an alpha- glucosidase inhibitor, voglibose. We 
found that BNP concentrations decreased after initia-
tion of either luseogliflozin or voglibose. There was no 
Figure 1. Study flow diagram.
BNP indicates B- type natriuretic peptide.
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significant difference in the degree of reduction in BNP 
concentrations after 12  weeks for luseogliflozin and 
voglibose. There were no significant differences in the 
main secondary and safety outcomes, except for gas-
trointestinal symptoms, between the groups.
Some randomized controlled trials reported that 
SGLT2 inhibitors robustly reduced cardiovascular ad-
verse events, including hospitalization of heart failure, 
in patients with diabetes mellitus.7–9 In an exploratory 
analysis from DECLARE- TIMI 58 (Dapagliflozin Effect 
on Cardiovascular Events–Thrombolysis in Myocardial 
Infarction 58), hospitalization for heart failure in patients 
with heart failure with reduced EF (<45%) at baseline 
was significantly reduced, while this reduction in hos-
pitalization for heart failure was not observed in pa-
tients with HFpEF.18 A recent randomized trial showed 
that dapagliflozin decreased worsening heart failure 
in patients with heart failure with reduced EF, regard-
less of the presence or absence of diabetes mellitus.10 
However, the benefit of an SGLT2 inhibitor in patients 
with HFpEF on hospitalization for heart failure remains 
unestablished. This study specifically focused on pa-
tients with HFpEF using BNP concentrations. Although 
BNP was a surrogate end point for heart failure, use of 
the primary outcome of the change in ratio of BNP con-
centrations after 12 weeks of treatment from baseline 
was a strength of this study. Additionally, selection of 
participants to clearly target patients with HFpEF was 
Luseogliflozin 
(n=83)
Voglibose 
(n=82)
P 
Value
Echocardiographic parameters
Left ventricular ejection 
fraction, %
57±9.4 58±9.4 0.41
≥50% 53/73 (73) 52/65 (80) 0.31
E/A 0.77±0.21 0.85±0.29 0.094
e′, cm/s 5.4±1.5 5.6±1.8 0.66
<8 cm/s 68/71 (96) 61/66 (92) 0.40
E/e′ 13.0±4.5 13.3±5.6 0.67
≥13 24/71 (34) 30/66 (46) 0.163
Left atrial diameter, mm 42.0±7.4 42.5±7.9 0.69
Left atrial volume index, 
mL/m2
37.9±16.3 38.4±13.5 0.84
>34 mL/m2 35/68 (52) 32/59 (54) 0.76
Left ventricular mass 
index, mL/m2
93.0±23.2 91.3±27.5 0.71
≥115 g/m2 for men or 
≥95 g/m2 for women
15/70 (21) 13/63 (21) 0.91
Data are presented as mean±standard deviation, n (%), or median 
(interquartile range). ACE indicates angiotensin- converting enzyme; ARB, 
angiotensin- receptor blocker; BNP, B-type natriuretic peptide; CRP, C- 
reactive protein; E/A, ratio of early to atrial mitral inflow velocity; E/e′, ratio 
of early mitral inflow velocity to mitral annular early diastolic velocity; GFR, 
glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; NT- 
proBNP, N- terminal pro- B- type natriuretic peptide; and NYHA, New York 
Heart Association.
Table 1. ContinuedTable 1. Baseline Characteristics of the Patients
Luseogliflozin 
(n=83)
Voglibose 
(n=82)
P 
Value
Age, y 71.7±7.7 74.6±7.7 0.017
Median (interquartile 
range)
72 (67–78) 75 (70–79) 0.027
>60 y, n (%) 77 (93) 80 (98) 0.152
Male, n (%) 55 (66) 48 (59) 0.31
Body weight, kg 64.6±12.7 63.5±13.1 0.57
Body mass index, kg/m2 25.4±4.3 25.3±4.4 0.85
Waist circumflex, cm 92.6±11.4 91.1±12.1 0.45
NYHA class, n (%) 0.44
I 0 0
II 79 (96) 81 (99)
III 3 (4) 1 (1)
IV 0 0
Duration of diabetes 
mellitus, mo
72 (22–130) 72 (36–138) 0.90
Prior diagnoses, n (%)
Hypertension 72 (89) 64 (79) 0.087
Hyperuricemia 20 (25) 24 (30) 0.48
Cardiovascular disease 48 (59) 50 (62) 0.75
Dyslipidemia 65 (80) 61 (75) 0.45
Chronic kidney disease 29 (36) 27 (33) 0.74
Hepatic disorder 9 (11) 3 (3.7) 0.072
Atrial fibrillation or flutter 18 (22) 15 (18) 0.59
Medications, n (%)
ACE inhibitor or ARB 51 (61) 47 (57) 0.59
Beta- blocker 53 (64) 47 (57) 0.39
MRA 19 (23) 20 (24) 0.82
Loop diuretic 19 (23) 19 (23) 0.97
Hydralazine 5 (6.0) 5 (6.1) 0.98
Antidiabetic medication 53 (65) 50 (61) 0.74
Hemodynamic parameters
Systolic blood pressure, 
mm Hg
131±17 128±14 0.168
Diastolic blood 
pressure, mm Hg
71±11 71±10 0.52
Heart rate, bpm 69±13 70±12 0.53
Laboratory data
Hemoglobin A1c, % 7.0±0.7 6.9±0.8 0.52
Hemoglobin, g/dL 13.5±1.6 13.1±1.6 0.114
Hematocrit, % 41.4±4.8 40.4±4.2 0.159
Blood urea nitrogen, 
mg/dL
17.7±5.5 19.1±6.0 0.119
Serum creatinine, mg/dL 0.94±0.30 0.96±0.29 0.70
Estimated GFR, mL/min 
per 1.73 m2
60.6±19.4 56.8±16.5 0.185
BNP, pg/mL 63.7 (46.8–115.8) 75.1 (42.4–120) 0.87
NT- proBNP, pg/mL 203 (123–389) 200 (121–502) 0.70
High- sensitivity CRP, 
mg/L
0.91 (0.41–1.79) 0.73 (0.25–1.66) 0.48
 (Continued)
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an advantage of this study. Under this specific study 
design, this study showed no significant effect on the 
change in BNP concentrations from baseline with an 
SGLT2 inhibitor compared with an alpha- glucosidase 
inhibitor.
We consider that there were various factors that 
reduced the effect of an SGLT2 inhibitor in this study. 
First, the majority of patients who were enrolled in 
our study were at low risk. Almost all patients had 
New York Heart Association class II symptoms and 
low BNP levels at baseline. Only 23% of patients were 
receiving a loop diuretic at baseline, and had rela-
tively lower use of angiotensin- converting enzyme in-
hibitors or angiotensin- receptor blockers at baseline. 
Additionally, a total of 40% patients did not have prior 
atherosclerotic cardiovascular disease. Previous re-
ports have shown greater effectiveness of SGLT2 in-
hibitors in patients with prior myocardial infarction or 
a high risk of atherosclerotic cardiovascular disease 
than in those without these conditions.19,20 Therefore, 
patients without these conditions may have had 
less effectiveness of SGLT2 inhibitors in this study. 
Second, in our study, luseogliflozin and voglibose re-
duced BNP levels by 9.0% and 1.9%, respectively, 
but this difference was not significant. One explana-
tion for this lack of significance is that this study was 
not sufficiently powered for moderate differences 
that were actually observed. With a power of 80% 
Table 2. Outcomes of the Patients in the 2 Groups
Luseogliflozin (n=83) Voglibose (n=82) P Value
Primary outcome, % (95% CI)
Change in ratio of BNP
After 4 wk from baseline −15.48 (−25.32 to −4.33) −0.13 (−11.56 to 12.78) 0.108
After 12 wk from baseline −9.0 (−20.0 to 3.4) −1.94 (−12.3 to 9.6) 0.26
After 24 wk from baseline −13.99 (−26.65 to 0.85) 0.31 (−12.80 to 15.38) 0.133
Main secondary efficacy outcomes, % (95% CI)
Change in E/e′ 5.20 (−5.83 to 16.24) 1.32 (−5.82 to 8.47) 0.85
Change in left ventricular ejection fraction 2.78 (−2.66 to 8.21) 2.95 (−1.38 to 7.30) 0.62
Change in body weight −0.84 (−2.54 to 0.85) −0.57 (−1.98 to 0.85) 0.67
Change in hemoglobin A1c −1.87 (−3.31 to −0.44) −1.19 (−3.18 to −0.81) 0.71
Safety outcomes n=84 n=82
Major adverse cardiovascular outcome 0 0
Hypoglycemic adverse events 0 1 (1.2) 0.49
Urinary tract infection 0 1 (1.2) 0.49
Any infection 1 (1.2) 1 (1.2) 1.0
Severe hypotension 1 (1.2) 0 1.0
Elevation of blood pressure 2 (2.3) 0 0.50
Gastrointestinal symptoms 0 6 (7.3) 0.013
Bone fracture 0 1 (1.2) 0.49
Fatigue 1 (1.2) 2 (2.4) 0.62
Thirst 1 (1.2) 0 1.0
Exploratory hemodynamic and biomarker outcomes, % (95% CI)
Change in systolic blood pressure −3.96 (−6.89 to −1.03) 0.54 (−2.23 to 3.32) 0.036
Change in heart rate 0.49 (−3.48 to 4.45) 2.62 (−1.56 to 6.80) 0.39
Change in estimated GFR −4.26 (−7.20 to −1.32) −0.83 (−3.35 to 1.69) 0.061
Change in NT- pro- BNP −8.43 (−19.84 to 4.60) −5.50 (−15.17 to 5.27) 0.56
Change in high- sensitivity CRP 22.47 (−1.65 to 52.52) 9.97 (−18.13 to 47.71) 0.55
Change in E/A 3.42 (−2.48 to 9.33) 6.95 (−1.78 to 15.7) 0.57
Change in e′ 1.22 (−9.08 to 11.5) 2.46 (−6.26 to 11.2) 0.82
Change in left atrial diameter 2.37 (−1.23 to 5.96) −1.34 (−5.17 to 2.49) 0.105
Change in left atrial volume index −4.49 (−14.6 to 5.62) −0.62 (−11.8 to 10.6) 0.51
Change in left ventricular mass index −4.23 (−11.9 to 3.41) 2.29 (−3.66 to 8.24) 0.31
Data are presented as 95% CIs or n (%). BNP indicates B- type natriuretic peptide; CRP, C- reactive protein; E/A, ratio of early to atrial mitral inflow velocity; 
E/e′, ratio of early mitral inflow velocity to mitral annular early diastolic velocity; GFR, glomerular filtration rate; and NT- proBNP, N- terminal pro- B- type natriuretic 
peptide.
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and a sample size of 86 per group, we could statis-
tically detect up to a 30% difference between the 2 
groups. Underpowered analysis is susceptible to a 
type II error. The effect size of a reduction in BNP 
concentrations in this study was lower than we ex-
pected, probably attributable to patients with mild 
heart failure.
In this study, HFpEF was defined as a left ven-
tricular EF ≥45%, BNP concentrations ≥35  pg/mL, 
and any symptoms. This definition was modified ac-
cording to the 2012 European Society of Cardiology 
(ESC) heart failure guidelines.13 The cutoff of the EF 
for definition of HFpEF in other clinical trials varied 
from 40% to 50%.1,4,21,22 The 2012 ESC heart fail-
ure guidelines stated that patients with HF and an 
EF ≥50% are considered as having HFpEF, while pa-
tients with an EF ranging from 35% to 50% repre-
sent a “gray area.”13 The 2013 US guideline stated 
that HFpEF included an EF >40%.5 Based on these 
documents, we recruited patients with an EF ≥45% 
as HFpEF. With regard to the relevance of structural 
heart disease, a comprehensive echocardiographic 
examination was recommended at enrollment in the 
study. We checked the presence of structural and 
functional echocardiographic measures as listed in 
the 2012 ESC heart failure guidelines.13 Patients who 
had at least 1 of these measurements, including left 
ventricular hypertrophy, left atrial enlargement, and 
left ventricular diastolic dysfunction, comprised 97% 
of the study population. Therefore, we consider that 
almost all of the study population fulfilled the diag-
nostic criteria of HFpEF in the 2012 ESC heart failure 
guidelines.13
Our study showed a reduction in BNP concen-
trations in the luseogliflozin group at 4 weeks, which 
suggested that SGLT2 inhibitors reduce cardiac 
load immediately after their introduction. Further, 
luseogliflozin significantly reduced systolic blood 
pressure compared with voglibose. However, echo-
cardiographic parameters of left ventricular systolic 
or diastolic function (eg, left ventricular EF and E/e′) 
were similar between the groups. Interestingly, the 
left atrial volume index and left ventricular mass 
index appeared to be reduced after luseogliflozin, 
but this was not significant. Our research group has 
reported that an SGLT2 inhibitor ameliorated car-
diac hypertrophy and fibrosis in hypertensive rats 
that were fed a high- fat diet.23 Some studies have 
also shown that SGLT2 inhibition improves arterial 
stiffness and achieves lowering of blood pressure in 
patients with diabetes mellitus.24–26 From the results 
of subgroup analyses, luseogliflozin use tended to 
be higher in patients with an older age, BNP levels 
>100 pg/mL at baseline, and atrial arrhythmia (atrial 
fibrillation or flutter). We consider that these patients’ 
characteristics are representative of heart failure 
with left ventricular diastolic dysfunction. Therefore, 
selectively using SGLT2 inhibitors might be benefi-
cial for such patients with severe left ventricular di-
astolic dysfunction or cardiac afterload, even those 
with HFpEF. Further detailed studies are required, 
including ongoing randomized controlled trials.27–29
This study has several limitations. First, this study 
was not blinded and was an open- label study. Second, 
the primary outcome of this study was the change in 
BNP concentrations after 12 weeks of treatment from 
baseline. This was a surrogate end point, and the 
follow- up duration was short. Third, the predefined 
sample size of 190 was not achieved. We started the 
study, which was designed to be conducted for almost 
2 years, for the enrollment period from December 2015. 
However, the study population did not reach a number 
required for sufficient statistical power during the pre-
specified enrollment period. Therefore, we extended 
the enrollment period to 3 years until September 2018. 
Unfortunately, the study included only 169 patients. 
We could not continue enrollment of new patients be-
cause of a shortage of funds. Fourth, there were more 
patients with mild heart failure in this study than ex-
pected. Therefore, differences between study groups 
might have been diminished. Furthermore, the effect 
of luseogliflozin on BNP levels in patients with diabetes 
mellitus and HFpEF might have been overestimated, 
and the sample size calculation might not have been 
sufficient for estimating differences between the study 
groups. Finally, the latest definition of HFpEF in the 
ESC heart failure guidelines has changed since 2012. 
In the 2016 ESC heart failure guidelines,6 patients with 
a left ventricular EF ranging from 40% to 49% are 
Figure 2. Change in BNP concentrations.
No significant difference was observed in the reduction in BNP 
concentrations after 12 weeks compared with baseline between 
the two groups. The ratio of the mean BNP value at week 12 to 
the baseline value was 0.79 in the luseogliflozin group and 0.87 
in the voglibose group (percent change, −9.0% vs −1.9%, ratio of 
change with luseogliflozin vs voglibose, 0.93; 95% CI, 0.78–1.10; 
P=0.26). BNP indicates B- type natriuretic peptide.
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newly defined as HF with midrange EF. On the basis of 
the latest ESC heart failure guidelines,6 24% of patients 
with a left ventricular EF of <50% in this study did not 
fulfill the definition of HFpEF.
In conclusion, in patients with type 2 diabetes melli-
tus and HFpEF, initiation of luseogliflozin does not sig-
nificantly reduce BNP concentrations over a 12- week 
follow- up compared with voglibose.
Figure 3. Subgroup analyses of the change in BNP concentrations.
Data on the change in ratio of BNP concentrations from baseline to 12  weeks with each treatment 
according to subgroup are shown. ASCVD indicates atherosclerotic cardiovascular disease; BNP, B- type 
natriuretic peptide; GFR, glomerular filtration rate; and HbA1c, hemoglobin A1c.
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Data S1. Study protocol. 
Prospective Comparison of Luseogliflozin and Alpha- glucosidase on the Management 
of Diabetic Patients with Chronic Heart Failure and Preserved Ejection Fraction 
 
I. Summary of study plan 
The MUSCAT-HF trial was a multi-center, prospective, open-label, randomized controlled 
trial to assess the effect of luseogliflozin compared with voglibose on left ventricular load in 
patients with type 2 diabetes mellitus (T2DM) and heart failure with preserved ejection 
fraction (HFpEF). 
 
II. Background of study plan 
Recent randomized controlled trials showed that sodium glucose cotransporter 2 (SGLT2) 
inhibitors reduced all-cause mortality, cardiovascular mortality, and hospitalization of heart 
failure in type 2 diabetes compared with placebo. These results indicated that SGLT2 
inhibitors may be effective in lowering glucose levels and reducing cardiovascular events, 
particularly in patients with heart failure. Given that these trials were not specifically 
designed to investigate the effect of SGLT2 inhibitors in heart failure patients, no detailed 
data on their effects in heart failure were obtained. 
 
III. Study plan 
1. Purpose 
The aim of this study was to evaluate the efficacy of luseogliflozin, an SGLT2 inhibitor, 
compared with voglibose, an alpha-glucosidase inhibitor, using brain natriuretic peptide 
(BNP) as the index of therapeutic effect in patients with T2DM and HFpEF. The results of 
this study will support a novel strategy for the treatment of heart failure using an SGLT2 
inhibitor, independent of its glucose-lowering effects. 
 
2. Study population 
The planned sample size of this study was 95 patients per group (190 patients in total). The 
recruitment of study patients was planned to take place from September 2015 to September 
2018. Patients aged 20 years with T2DM (hemoglobin A1c [HbA1C] 9.0%) and HFpEF 
(left ventricular ejection fraction 45%) needing additional treatment for T2DM despite the 
ongoing treatment are eligible for participation. The key inclusion and exclusion criteria are 
detailed in Table 1. Given that the definition of chronic heart failure according to European 
Society of Cardiology guidelines includes BNP 35 pg/ml, patients with BNP <35 pg/ml was 
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excluded from this study. Study candidates were assessed for eligibility within 4 weeks prior 
to enrolment. 
 
Inclusion and exclusion criteria 
Inclusion criteria 
1) Diagnosis of T2DM and left ventricular ejection fraction >45% with current or previous 
symptoms of heart failure (dyspnea on effort, orthopnea, or leg edema) 
2) Inadequately controlled T2DM in patients who have received diet and exercise therapy, a 
lifestyle modification program, and hypoglycemic medications based on standard guidelines 
of the Japan Diabetes Society 
3) Age >20 years  
4) Provision of written informed consent prior to participation  
Exclusion criteria 
1) BNP <35 pg/ml 
2) Use of alpha-glucosidase inhibitors, SGLT2 inhibitors, glinides, or high-dose sulfonylurea  
3) Renal insufficiency (eGFR <30 ml/min/1.73m2)  
4) Left ventricular ejection fraction <45%  
5) History of severe ketoacidosis or diabetic coma within 6 months prior to participation  
6) Serious infection or severe trauma, or perioperative patients 
7) Type 1 diabetes mellitus 
8) Poorly controlled T2DM (HbA1c >9.0%)  
9) Uncontrolled hypertension (systolic blood pressure >160 mmHg) 
10) History of stroke, myocardial infarction, or severe cardiovascular disease with 
hospitalization within 6 months prior to participation 
11) Women who are pregnant or breastfeeding  
12) Allergy to either investigation product 
13) Other medical reason at the investigator’s discretion 
T2DM, type 2 diabetes mellitus; BNP, brain natriuretic peptide; SGLT2, sodium/glucose 
cotransporter 2; eGFR, estimated glomerular filtration rate; HbA1C, hemoglobin A1C 
 
3. Consent 
1) Written informed consent is needed to be received. 
2) If patients do not have ability of judgment, informed consent cannot be received. 
Informed Consent Form 
1 Purpose 
2 Efficacy and side effect  
3 Alternative treatment options 
4 NO disadvantage by rejection 
5 Withdrawal rights 
6 Ethics 
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4. Interventions 
1) Voglibose: subjects who receive voglibose (2.5 mg once daily) 
2) Luseogliflozin: subjects who receive luseogliflozin (2.5 mg once daily) 
 
5. Methods 
Patients fulfilling all criteria who provide written informed consent to participate in this study 
were enrolled and subsequently randomized (1:1) to receive luseogliflozin (2.5 mg once 
daily) or voglibose (0.2 mg three times daily) in addition to their background medication. 
Randomization was performed using a computer-generated random sequence web response 
system. Patients were stratified by age (<65 years, ≥65 years), baseline HbA1c (<8.0%, 
≥8.0%), baseline BNP (<100 pg/ml, ≥100 pg/ml), baseline renal function (eGFR ≥60 
ml/min/1.73 m2, <60 ml/min/1.73 m2), use of thiazolidine or not, and presence or absence of 
atrial fibrillation (AF) and flutter (AFL) at screening. 
 Assessments during the study period are listed in Figure 1. Laboratory data, 
electrocardiogram, echocardiography and patients’ vital signs, body weight, and waist 
circumference, were evaluated at 4 ± 2 weeks (visit 29 ± 14 days) and 12 weeks (visit 85 ± 28 
days) after initiation of study treatment. Safety and tolerability were assessed during the 
treatment period. The primary outcome of change in BNP compared with baseline was 
evaluated at 12 weeks (visit 85 ± 28 days) and patients were followed up for an additional 12 
weeks (visit 169 ± 28 days) after the end of treatment. If a patient’s glycemic control worsens 
after 4 ± 2 weeks, the investigator could increase the dose of allocated treatment (to 
luseogliflozin 5 mg once daily or voglibose 0.3 mg three times daily) and other specific 
T2DM drugs, except for sulfonylureas. Investigators were also encouraged to treat all other 
cardiovascular risk factors according to local standard of care. Under the following 
circumstances, the investigator must evaluate the data and patient’s vital sign: 1) 
discontinuation of study treatment; 2) dose increase of specific treatment for heart failure; 3) 
initiation of new treatment for heart failure; 4) withdrawal from the study. The permitted 
medications for the treatment of heart failure included angiotensin-converting enzyme 
inhibitors, angiotensin receptor blockers, beta-blockers, diuretics, and 
mineralocorticoid/aldosterone receptor antagonists. 
 
6. End points 
Assessments during the study period are listed in Figure 2. 
Primary outcome  
The primary outcome of this study was the difference in BNP after 12 weeks (visit 85±28 
days) of treatment between the luseogliflozin and the voglibose groups, defined as the 
difference in logarithmic BNP change calculated as follows: 
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(*) BNP proportional change = BNP (at follow-up)/ BNP (at baseline), 
(†) Logarithmic BNP change = logarithmic BNP (at follow-up) – logarithmic BNP (at 
baseline), 
In other words, (*) = exponential (†). 
 
Furthermore, we calculated the ratio of BNP change rate 
(‡) The ratio of BNP proportional change (the luseogliflozin group to the voglibose group) 
= (*) (in the luseogliflozin group)/(*) (in the voglibose group), 
(§) The difference of logarithmic BNP change = (†) (in the luseogliflozin group) – (†) (in 
the voglibose group), 
In other words, (‡) = exponential (§) 
 
Secondary outcomes 
The key secondary outcomes of this study were the differences in the following parameters 
between the luseogliflozin and the voglibose groups:  
1) Ratio of early mitral inflow velocity to mitral annular early diastolic velocity (E/e')  
2) Left ventricular ejection fraction 
3) Body weight 
4) HbA1c  
 
The difference in E/e' and HbA1c between the groups was defined as the difference in 
logarithmic E/e' and HbA1c using the same calculation as for BNP. The difference in body 
weight and left ventricular ejection fraction was defined as the difference between those 
parameters at follow-up and at baseline. Further exploratory analysis is listed in exploratory 
analysis section. 
Safety outcomes: including, but not limited to: 
• clinical laboratory tests, vital signs, 12-lead electrocardiogram (ECG), physical 
examination, and the use of rescue medication 
• Adverse events including major adverse cardiovascular events (MACE), 
hypoglycemic adverse events (requiring any intervention), and urinary tract infection. 
Safety was assessed based on adverse events reported throughout the study, clinical 
laboratory tests, vital signs, 12-lead electrocardiogram, physical examination, and the use of 
rescue medication. Prespecified adverse events included MACE, hypoglycemic adverse 
events (requiring any intervention), and urinary tract infection (details listed in Outcome 
definitions for adverse events section) 
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7. Cancellation and withdrawal 
Discontinuance criteria 
Withdrawal 
criteria 
1) Inadequate glycemic control after administration of the study drug 
 2) Suspect of adverse side effects of the study drug 
 3) Frequent hypoglycemia 
 4) Onset of adverse cardiovascular event† 
 5) Declaration of withdrawal from the study by the participant  
 6) Turning out of misunderstanding of all criteria for eligibility after 
enrollment  
 7) Pregnancy after enrollment 
 8) Lower adherence for administration of the study drug (< 70%) 
 9) Assessment of inadequate for the study by the attending doctor 
    
†Cardiovascular 
event  
1) Addition of heart failure treatment drugs as follows; 
  angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARB), beta-blockers, diuretics, and aldosterone antagonists  
 2) Hospitalization of heart failure 
 
8. Study period 
Between December 1, 2015 and March 31, 2019 
 
9. Statistics 
Sample size and power calculation 
The primary hypothesis of this study was that the SGLT2 inhibitor luseogliflozin could 
reduce cardiac load in patients with T2DM and HFpEF. Therefore, the primary outcome was 
the difference in change in BNP from baseline to 12 weeks between patients receiving 
luseogliflozin or voglibose. As of the start of recruitment in September 2015, no 
interventional study of the effect of SGLT2 inhibitors on heart failure in patients with T2DM 
had been reported. Therefore, we had estimated that BNP change rate in the luseogliflozin 
group would be 30% lower as compared with that in the globose group according to previous 
studies of the effect of renin-angiotensin-aldosterone system inhibitors on heart failure 15-17. 
The standard deviation of the natural logarithmic transformation of BNP was estimated at 
0.83, in reference to the PARAMOUNT study17. A minimum of 172 patients (86 patients per 
group) is required to provide 80% power with a two-sided ɑ level of 0.05 by Student’s t-test 
on the ratio of BNP change rate between the luseogliflozin and voglibose groups. With 10% 
of patients estimated to withdraw from participation during the study period, the final 
enrolment target was set at 190 patients (95 patients per group). 
 
Analysis plan 
In the efficacy analysis, the primary population comprised the Full Analysis Set (FAS), 
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defined as all randomized patients who received one dose of study drug and were followed up 
at least once. Patients with no BNP data and patients who withdrew or discontinue treatment 
was excluded from the FAS. Missing values at 4, 12, and 24 weeks were replaced by the last 
observed value for that variable (last observation carried forward). In the primary outcome 
analysis, baseline observation carried forward analysis was also performed. Efficacy analysis 
was performed according to the treatment to which patients are randomly assigned, based on 
the intention-to-treat analysis. The primary outcome analysis was based on an analysis of 
covariance (ANCOVA) (α = 0.05, level of significance) for the ratio of BNP change rate in 
the FAS. Adjusted covariates included the assigned treatment (luseogliflozin, voglibose), 
baseline age (<65 or ≥65 years), baseline HbA1c (<8.0 or ≥8.0%), baseline BNP (<100 or 
≥100 pg/ml), baseline renal function (eGFR ≥60 or <60 ml/min/1.73 m2), use of thiazolidine 
or not at baseline, and presence or absence of AF and AFL at baseline as stratified factors of 
randomization. Furthermore, BNP change rate, ratio of BNP change rate, and 95% confidence 
intervals were calculated. The same ANCOVA analysis as for the primary outcome was 
performed for the ratio of BNP change rate at 4 weeks and 24 weeks between the two groups.  
 Prespecified subgroup analyses were performed on the primary outcome using 
ANCOVA (covariates: assigned treatment and BNP at screening) in the following subgroups: 
baseline age (<65 or ≥65 years), baseline HbA1c (<8.0 or ≥8.0%), baseline BNP (<100 or 
≥100 pg/ml), baseline renal function (eGFR ≥60 or <60 ml/min/1.73 m2), use of thiazolidine 
or not at baseline, baseline body weight (<60 kg, ≥60 kg), and presence or absence of AF and 
AFL at baseline. Furthermore, exploratory analysis on the primary outcome was performed in 
subgroups based on blood pressure, heart rate, waist circumference, cardiovascular risk 
factors (hypertension, T2DM, hyperuricemia, family history, and smoking), alcohol 
consumption, regular medication, and serum lipid levels (details listed in exploratory analysis 
section). 
 The key secondary outcomes, difference in E/e', left ventricular ejection fraction, 
body weight, and HbA1C at 12 weeks between the luseogliflozin and voglibose groups, were 
analyzed using the same ANCOVA as for the primary outcome. Subgroup analysis for the key 
secondary outcomes was performed in the same subgroups as for the primary outcome 
analysis. The following secondary outcomes was also analyzed using the same analysis plan: 
E/e', left ventricular ejection fraction, body weight, and HbA1C at 4 and 24 weeks; and 
exploratory parameters at 4, 12, and 24 weeks. 
 For the safety analysis, the primary population was the Safety Analysis Set 
(SAFETY), defined as all patients who receive at least one dose of study drug. Although 
patients who withdrew without receiving study drug will be excluded from SAFETY, other 
patients who withdrew for any other reason was included. The safety analysis was performed 
according to the treatment administered to patients in practice, based on the as-treated 
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analysis. Analysis of SAEs (MACE, hypoglycemia, and urinary tract infection) was 
performed using the Cochran–Mantel–Haenszel test with stratification factors of age (<65 or 
≥65 years), baseline HbA1c (<8.0 or ≥8.0%), baseline BNP (<100 or ≥100 pg/ml), baseline 
renal function (eGFR ≥60 or <60 ml/min/1.73 m2), use of thiazolidine or not, and presence or 
absence of AF and AFL at screening. 
 All comparisons were planned, and the analyses was two sided With P values <0.05 
considered statistically significant. All statistical analyses were performed using IBM SPSS 
Statistics 24 (IBM, Armonk, NY) and Stata/SE 15.1 for Mac (StataCorp, College Station, 
TX). The statistical analysis plan was developed by the principal investigator and a 
biostatistician prior to the completion of patient recruitment and database lock. 
 
Exploratory analysis 
Further exploratory analysis in this study was planned for such parameters. 
1) Blood glucose  
2) Lipid metabolism [total cholesterol, high density lipoprotein, triglyceride, small dense 
low-density lipoprotein and Malondialdehyde-modified low density lipoprotein] 
3) Blood pressure 
4) High sensitive CRP 
5) Adiponectin, microalbuminuria 
6) Urinary 8-hydroxy-2' –deoxyguanosine 
7) Estimated GFR 
 
10. Data management and analysis 
Members of the Steering Committee also designed the study and were responsible for its 
conduction (details listed in Study organization section). Significant adverse events (SAEs) 
occurring within 30 days after final administration of the study drug or after 30 days with a 
suspicion of association with the study drug, as well as all pregnancies, was immediately 
reported to the Steering Committee and the sponsor by the investigator, in accordance with 
GCP. 
 
11. Ethical consideration 
All participants provided written informed consent before enrolling.  
This study was conducted according to the principles expressed in the Declaration of 
Helsinki. 
This study was approved by the Okayama University Graduate School of Medicine, Density 
and Pharmaceutical Sciences and the Okayama University Hospital Ethics Committee, as 
well as the ethics committee of each participating center. Trial registration: UMIN Clinical 
Trials Registry (UMIN-CTR), UMIN000018395, https://upload.umin.ac.jp/cgi-open-
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bin/ctr_e/ctr_view.cgi?recptno=R000021301 
 
12. Methods of plan change 
When needed, investigators made a discussion and decision of plan change. 
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Data S2. Laboratory testing 
 
Brain natriuretic peptide, N-terminal brain natriuretic peptide, adiponectin, small dense low-
density lipoprotein, malondialdehyde-modified low density lipoprotein, high-sensitive C-
reactive protein, microalbuminuria, urinary 8-hydroxy-2' –deoxyguanosine 
These parameters were measured in a central laboratory (SRL, Inc. Hachioji, Tokyo, Japan). 
 
White blood cell, red blood cell, platelet, hemoglobin, hematocrit, aspartate aminotransferase, 
alanine aminotransferase, lactate dehydrogenase, blood urea nitrogen, serum creatinine, uric 
acid, serum sodium, serum potassium, serum chloride, total cholesterol, high density 
lipoprotein, triglyceride, total protein, albumin, blood sugar, glycohemoglobin 
These parameters were measured in each institution. 
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Data S3. Outcome definition of adverse events 
 
Major adverse cardiovascular events (MACE) include cardiovascular death, acute coronary 
syndrome, hospitalization of heart failure, and stroke. 
 
• Cardiovascular death  
The cause of death will be determined by the principal condition that caused the death, not 
the immediate mode of death. Clinical Events Committee (CEC) members will review all 
available information and use their clinical expertise to adjudicate the cause of death. All 
deaths not attributed to the categories of cardiovascular (CV) death and not attributed to a 
non-CV cause are presumed CV deaths and are part of the CV mortality outcome. Death 
certificates or summaries, if possible, including the date of death and other relevant details, 
will be provided for all patients who have died. However, if a death certificate is the only 
information available for review in addition to the patient data in the clinical trial database, 
the CEC may decide not to use this information as cause of death if another etiology appears 
more plausible. The following definitions will be used for the adjudication of fatal cases: 
 
Sudden cardiac death. Death that occurs unexpectedly in a previously stable patient and 
includes the following:  
• Witnessed and instantaneous death without new or worsening symptoms  
• Witnessed death within 60 minutes of the onset of new or worsening cardiac 
symptoms  
• Witnessed death attributed to an identified arrhythmia (e.g., captured by 
electrocardiogram or witnessed on a monitor by either a medic or paramedic)  
• Subject unsuccessfully resuscitated from cardiac arrest or successfully resuscitated 
from cardiac arrest that dies within 24 hours without identification of a non-cardiac etiology  
• Un-witnessed death with no conclusive evidence of another, non-CV, cause of death 
(i.e. presumed CV death).  
 
Sudden death attributable to acute myocardial infarction (MI) (MI type 3). Sudden death 
occurring up to 14 days after a documented acute MI (verified either by the diagnostic criteria 
outlined for acute MI or by autopsy findings showing recent MI or recent coronary thrombus) 
where there is no conclusive evidence of another cause of death. If death occurs before the 
biochemical confirmation of myocardial necrosis can be obtained, adjudication should be 
based on clinical presentation and ECG evidence.  
 
Death attributable to heart failure or cardiogenic shock. Death occurring in the context of 
clinically worsening symptoms and/or signs of congestive heart failure (CHF) without 
evidence of another cause of death.  
New or worsening signs and/or symptoms of CHF include any of the following:  
• New or increasing symptoms and/or signs of heart failure requiring the initiation of, 
or an increase in, treatment directed at heart failure or occurring in a patient already receiving 
maximal therapy for heart failure  
• Heart failure symptoms or signs requiring continuous intravenous therapy or oxygen 
administration  
• Confinement to bed predominantly because of heart failure symptoms  
• Pulmonary edema sufficient to cause tachypnea and distress not occurring in the 
context of an acute MI or as the consequence of an arrhythmia occurring in the absence of 
worsening heart failure  
• Cardiogenic shock not occurring in the context of an acute MI or as the consequence 
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of an arrhythmia occurring in the absence of worsening heart failure 
– Cardiogenic shock is defined as systolic blood pressure (SBP) <90 mmHg for more 
than 1 hour, ack of response to fluid resuscitation and/or heart rate correction, and judged to 
be secondary to cardiac dysfunction and associated with at least one of the following signs of 
hypoperfusion:  
1. Cool, clammy skin 
2. Oliguria (urine output <30 mL/hour) 
3. Altered sensorium 
4. Cardiac index <2.2 L/min/m2  
Cardiogenic shock can also be defined in the presence of SBP ≥90 mmHg or for a time 
period <1 hour if the blood pressure measurement or time period is influenced by the 
presence of positive inotropic or vasopressor agents alone and/or with mechanical support <1 
hour. The outcome of cardiogenic shock will be based on CEC assessment and must occur 
after randomization. Episodes of cardiogenic shock occurring before and continuing after 
randomization will not be part of the study outcome. This category will include sudden death 
occurring during an admission for worsening heart failure  
 
Death attributable to stroke or cerebrovascular event. Death occurring up to 30 days after a 
stroke that is either attributable to the stroke or caused by a complication of the stroke.  
 
Death attributable to other CV causes. Death must be caused by a fully documented CV event 
not included in the above categories (e.g. dysrhythmia, pulmonary embolism, or CV 
intervention). Death attributable to an MI that occurs as a direct consequence of a CV 
investigation/procedure/operation will be classified as death due to another CV cause.  
 
Non-CV death  
Non-CV death is defined as any death not covered by cardiac death or vascular death. The 
CEC will be asked to determine the most likely cause of non-CV death. Examples of non-CV 
death are pulmonary causes, renal causes, gastrointestinal causes, infection (including sepsis), 
non-infectious causes (e.g., systemic inflammatory response syndrome), malignancy (i.e., 
new malignancy, worsening of prior malignancy), hemorrhage (not intracranial), 
accidental/trauma, suicide, non-CV organ failure (e.g., hepatic failure) or non-CV surgery. 
 
• Acute coronary syndrome 
ACS includes MI and unstable angina.  
 
MI (non-fatal) 
The term MI should be used when there is evidence of myocardial necrosis in a clinical 
setting consistent with myocardial ischemia. Under these conditions, any one of the following 
criteria (A to C) meets the diagnosis for myocardial infarction. 
 
A. Spontaneous MI (type 1) 
To identify a type 1 MI, patients should demonstrate spontaneous symptoms of myocardial 
ischemia unprovoked by supply/demand inequity, together with ≥1 of the following criteria: 
• Cardiac biomarker elevation: Troponin is the preferred marker for adjudicating the 
presence of acute MI. At least one value should show a rise and/or fall from the lowest cut-
point providing 10% imprecision (typically the upper reference limit for the troponin run per 
standard of clinical care). Creatine kinase-MB is a secondary choice of marker to troponin; a 
rise in CK-MB above the local upper reference limit would be consistent with myocardial 
injury. 
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• ECG changes consistent with new ischemic changes 
– ECG changes indicative of new ischemia (new ST-T changes or new left bundle 
branch block [LBBB]) or ECG manifestations of acute myocardial ischemia (in the absence 
of left ventricular hypertrophy [LVH] and LBBB):  
– Development of pathological Q waves in the ECG 
1. Any Q-wave in leads V2–V3 ≥0.02 seconds or QS complex in leads V2 and V3 
2. Q-wave ≥0.03 seconds and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-
V6 in any two leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF) 
– ST elevation: New ST elevation at the J-point in two contiguous leads with the cut-
off points: ≥0.2 mV in men or ≥0.15 mV in women in leads V2–V3 and/or ≥0.1 mV in other 
leads 
– ST depression and T-wave changes: New horizontal or down-sloping ST depression 
≥0.05 mV in two contiguous leads and/or T inversion ≥0.1 mV in two contiguous leads with 
prominent R-wave or R/S ratio >1 
• Imaging evidence of new non-viable myocardium or new wall motion abnormality 
 
B. “Demand”-related (type 2) MI 
Patients with type 2 MI should be considered under similar diagnostic criteria as a type 1 MI; 
however, type 2 MI should be considered present when myocardial ischemia and infarction 
are consequent to supply/demand inequity, rather than a spontaneous plaque rupture and 
coronary thrombosis. 
 
C. Percutaneous coronary intervention (PCI)-related MI (type 4a/4b) 
For PCI in patients with normal baseline troponin values, elevations of cardiac biomarkers 
above the 99th percentile URL within 24 hours of the procedure are indicative of peri-
procedural myocardial necrosis. By convention, increases of biomarkers >3 × 99th percentile 
URL (troponin or CK-MB >3 × 99th percentile URL) are consistent with PCI-related MI. 
Where the cardiac biomarker is elevated prior to PCI, a ≥20% increase in the value of the 
second cardiac biomarker sample within 24 hours of PCI and documentation that cardiac 
biomarker values were decreasing (two samples ≥6 hours apart) prior to the suspected 
recurrent MI are consistent with PCI-related MI. 
Symptoms of cardiac ischemia are not required. 
 
D. Coronary artery bypass grafting (CABG)-related MI (type 5) 
For CABG in patients with normal baseline troponin values, elevation of cardiac biomarkers 
above the 99th percentile URL within 72 hours of the procedure is indicative of peri-
procedural myocardial necrosis. By convention, an increase of biomarkers >5 × 99th 
percentile URL (troponin or CK-MB >5 × 99th percentile URL) plus at least one of the 
following is consistent with CABG-related MI: 
• New pathological Q waves in at least two contiguous leads on the ECG that persist 
for 30 days, or new LBBB 
• Angiographically documented new graft or native coronary artery occlusion 
• Imaging evidence of new loss of viable myocardium 
 
If the cardiac biomarker is elevated prior to CABG, a ≥20% increase in the value of the 
second cardiac biomarker sample within 72 hours of CABG and documentation that cardiac 
biomarker values were decreasing (two samples ≥6 hours apart) prior to the suspected 
recurrent MI plus new pathological Q-waves in ≥2 contiguous leads on the 
electrocardiogram; or new LBBB, angiographically documented new graft, or native 
coronary artery occlusion; or imaging evidence of new loss of viable myocardium are 
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consistent with a periprocedural MI after CABG. Symptoms of cardiac ischemia are not 
required. 
 
Clinical classification of acute MI. Every MI identified by the CEC will be classified into one 
of the following categories: 
• Type 1: Spontaneous MI related to ischemia arising from a primary coronary event 
such as plaque erosion and/or rupture, fissuring, or dissection 
• Type 2: MI secondary to ischemia attributable to either increased oxygen demand or 
decreased supply, e.g. coronary artery spasm, coronary embolism, anemia, arrhythmias, 
hypertension, or hypotension 
• Type 3: Sudden unexpected cardiac death, including cardiac arrest, often with 
symptoms suggestive of myocardial ischemia, accompanied by presumably new ST 
elevation, new LBBB, or evidence of fresh thrombus in a coronary artery by angiography 
and/or at autopsy, with death occurring before blood samples could be obtained or before the 
appearance of cardiac biomarkers in the blood 
• Type 4a: MI associated with PCI 
• Type 4b: MI associated with stent thrombosis as documented by angiography or at 
autopsy 
• Type 5: MI associated with CABG 
 
Hospitalization for unstable angina  
The date of this event will be the day of hospitalization of the patient including any overnight 
stay at an emergency room or chest pain unit. Unstable angina requiring hospitalization is 
defined as all of the following:  
• No elevation in cardiac biomarkers (cardiac biomarkers negative for myocardial 
necrosis) according to conventional assays or contemporary sensitive assays 
• Clinical presentation: Cardiac symptoms lasting ≥10 minutes and considered to be 
myocardial ischemia upon final diagnosis with one of the following: 
– Rest angina 
– New-onset (<2 months) severe angina (Canadian Cardiovascular Society [CCS] 
Grading Scale, or CCS classification system, classification severity ≥III) 
– Increasing angina (in intensity, duration, and/or frequency) with an increase in 
severity of >1 CCS class to CCS class >III 
• Angina requiring an unscheduled visit to a healthcare facility and overnight 
admission  
• At least one of the following:  
– New or worsening ST or T-wave changes by ECG. ECG changes should satisfy the 
following criteria for acute myocardial ischemia in the absence of LVH and LBBB: 
1. ST elevation: New transient (known to be <20 minutes) ST elevation at the J-point in two 
contiguous leads with cut-off points of ≥0.2 mV in men or ≥0.15 mV in women in leads 
V2–V3 and/or ≥0.1 mV in other leads  
2. ST depression and T-wave changes: New horizontal or down-sloping ST depression 
≥0.05 mV in two contiguous leads; and/or T inversion ≥0.1 mV in two contiguous leads 
with prominent R-wave or R/S ratio >1  
– Evidence of ischemia on stress testing with cardiac imaging  
– Evidence of ischemia on stress testing with angiographic evidence of ≥70% lesion 
and/or thrombus in an epicardial coronary artery or initiation/increased dosing of antianginal 
therapy 
– Angiographic evidence of ≥70% lesion and/or thrombus in an epicardial coronary 
artery  
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• Heart failure requiring hospitalization 
The date of this event will be the day of hospitalization of the patient including any overnight 
stay at an emergency room or chest pain unit. Heart failure requiring hospitalization is 
defined as an event that meets all of the following criteria:  
• Requires hospitalization defined as an admission to an inpatient unit or a visit to an 
emergency department that results in at least a 12-hour stay (or a date change if the time of 
admission/discharge is not available) 
• Clinical manifestations of heart failure (new or worsening), including at least one of 
the followings:  
– Dyspnea 
– Orthopnea 
– Paroxysmal nocturnal dyspnea 
– Edema 
– Pulmonary basilar crackles 
– Jugular venous distension 
– Third heart sound or gallop rhythm 
– Radiological evidence of worsening heart failure 
• Additional/increased therapy: at least one of the followings: 
– Initiation of oral diuretic, intravenous diuretic, inotrope, or vasodilator therapy 
– Up-titration of oral diuretic or intravenous therapy, if already on therapy 
– Initiation of mechanical or surgical intervention (mechanical circulatory support, 
heart transplantation, or ventricular pacing to improve cardiac function); or the use of 
ultrafiltration, hemofiltration, or dialysis that is specifically directed at the treatment of heart 
failure 
Changes in a biomarker (e.g., brain natriuretic peptide) consistent with CHF will support this 
diagnosis. 
 
 
Transient ischemic attack (TIA) 
A transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal 
ischemia, without acute infarction. 
 
• Stroke 
The rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral 
blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, 
tumor, or infection). Available neuroimaging studies will be considered to support the clinical 
impression and to determine if there is a demonstrable lesion compatible with an acute stroke. 
Strokes will be classified as ischemic, hemorrhagic, or unknown. 
 
Diagnosis of stroke. For the diagnosis of stroke, the following four criteria should be 
fulfilled: 
• Rapid onset of a focal/global neurological deficit with at least one of the following: 
– Change in level of consciousness 
– Hemiplegia 
– Hemiparesis 
– Numbness or sensory loss affecting one side of the body 
– Dysphasia/aphasia 
– Hemianopia (loss of half of the field of vision of one or both eyes) 
– Other new neurological sign(s)/symptom(s) consistent with stroke 
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Note: If the mode of onset is uncertain, a diagnosis of stroke may be made provided that there 
is no plausible non-stroke cause for the clinical presentation 
• Duration of a focal/global neurological deficit ≥24 hours OR <24 hours if 
attributable to at least one of the following therapeutic interventions:  
– Pharmacologic (i.e., thrombolytic drug administration)  
– Non-pharmacologic (i.e., neurointerventional procedure such as intracranial 
angioplasty) 
or 
– Available brain imaging clearly documents a new hemorrhage or infarct  
or 
– The neurological deficit results in death 
• No other readily identifiable non-stroke cause for the clinical presentation (e.g., 
brain tumor, trauma, infection, hypoglycemia, peripheral lesion) 
• Confirmation of the diagnosis by at least one of the following:* 
– Neurology or neurosurgical specialist 
– Brain imaging procedure (at least one of the followings): 
1 CT scan 
2 MRI scan 
3 Cerebral vessel angiography 
– Lumbar puncture (i.e. spinal fluid analysis diagnostic of intracranial hemorrhage) 
If a stroke is reported but evidence of confirmation of the diagnosis by the methods outlined 
above is absent, the event will be discussed at a full CEC meeting. In such cases, the event 
may be adjudicated as a stroke on the basis of the clinical presentation alone, but full CEC 
consensus will be mandatory. 
 
If the acute focal signs represent a worsening of a previous deficit, these signs must have 
either 
• Persisted for more than one week 
OR 
• Persisted for more than 24 hours and accompanied by an appropriate new CT or 
MRI finding 
 
Classification of stroke. Strokes are sub-classified as follows: 
• Ischemic (non-hemorrhagic): A stroke caused by an arterial obstruction attributable 
to either a thrombotic (e.g., large vessel disease/atherosclerotic or small vessel 
disease/lacunar) or embolic etiology. This category includes ischemic stroke with 
hemorrhagic transformation (i.e. no evidence of hemorrhage on an initial imaging study but 
appearance on a subsequent scan) 
• Hemorrhagic: A stroke caused by a hemorrhage in the brain as documented by 
neuroimaging or autopsy. This category will include strokes attributable to primary 
intracerebral hemorrhage (intraparenchymal or intraventricular), subdural hematoma and 
primary subarachnoid hemorrhage 
• Not assessable: The stroke type could not be determined by imaging or other means 
(e.g., lumbar puncture, neurosurgery, or autopsy) or no imaging was performed. 
 
Hypoglycemic adverse events (requiring any intervention) 
Hypoglycemic adverse events are defined as the requirement of high-sugar food, drinks, or 
glucose because of a very low level of blood glucose.  
Representative symptoms of hypoglycemia may include: 
– Irregular heart rhythm 
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– Fatigue 
– Pale skin 
– Shakiness 
– Anxiety 
– Sweating 
– Hunger 
– Irritability 
– Tingling sensation around the mouth 
– Crying out during sleep 
 
Urinary tract infection 
Urinary tract infection is defined as the requirement of antibiotics because of infectious 
episodes in any part of the urinary system (kidneys, ureters, bladder, or urethra). 
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Figure S1. Study design. 
 
 
 
Arrows illustrate patients’ flow and the timing of follow-up. Patients with type 2 diabetes 
mellitus are screened whether with heart failure with preserved ejection fraction or without 
(screening period, yellow arrow). One of the study drugs was administered to patients met 
inclusion criteria after collection of baseline data within one week after randomization (grey 
arrow). After administration, mandatory follow-up period is for 12 weeks (study follow-up 
period, blue arrow). After 12 weeks, expanding follow-up are continued in patients agreed 
with (Arrow with dotted line). ECG, electrocardiogram. 
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Table S1. Assessments during the study period. 
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